WO2008099071A8 - Anticorps monoclonal dirigé contre le récepteur humain des ldl - Google Patents

Anticorps monoclonal dirigé contre le récepteur humain des ldl Download PDF

Info

Publication number
WO2008099071A8
WO2008099071A8 PCT/FR2007/002187 FR2007002187W WO2008099071A8 WO 2008099071 A8 WO2008099071 A8 WO 2008099071A8 FR 2007002187 W FR2007002187 W FR 2007002187W WO 2008099071 A8 WO2008099071 A8 WO 2008099071A8
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
directed against
antibody directed
nucleic acid
human ldl
Prior art date
Application number
PCT/FR2007/002187
Other languages
English (en)
Other versions
WO2008099071A2 (fr
WO2008099071A3 (fr
Inventor
Christophe De Romeuf
Christian Behrens
Original Assignee
Lfb Biotechnologies Societe Par Actions Simplifiee Unipersonnelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies Societe Par Actions Simplifiee Unipersonnelle filed Critical Lfb Biotechnologies Societe Par Actions Simplifiee Unipersonnelle
Priority to AU2007346741A priority Critical patent/AU2007346741A1/en
Priority to JP2009543504A priority patent/JP2010514434A/ja
Priority to CN200780048492A priority patent/CN101679524A/zh
Priority to CA002661853A priority patent/CA2661853A1/fr
Priority to EP07872460A priority patent/EP2167544A2/fr
Priority to US12/519,275 priority patent/US20100098706A1/en
Publication of WO2008099071A2 publication Critical patent/WO2008099071A2/fr
Publication of WO2008099071A3 publication Critical patent/WO2008099071A3/fr
Publication of WO2008099071A8 publication Critical patent/WO2008099071A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un anticorps monoclonal dirigé contre le récepteur humain des LDL (Low Density Lipoprotein), dans lequel la région variable de chacune de ses chaînes légères est codée par la séquence d'acide nucléique murine SEQ ID NO : 5, la région variable de chacune de ses chaînes lourdes est codée par la séquence d'acide nucléique murine SEQ ID NO : 7, ou par des séquences d'acide nucléique présentant une homologie suffisante avec les séquences SEQ ID NO : 5 et SEQ ID NO : 7 pour que la nature et l'affinité de la liaison dudit anticorps à son antigène ne soient pas modifiées, et les régions constantes de ses chaînes légères et de ses chaînes lourdes sont des régions constantes provenant d'une espèce non-murine.
PCT/FR2007/002187 2006-12-29 2007-12-28 Anticorps monoclonal dirigé contre le récepteur humain des ldl WO2008099071A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007346741A AU2007346741A1 (en) 2006-12-29 2007-12-28 Monoclonal antibody directed against the human LDL receptor
JP2009543504A JP2010514434A (ja) 2006-12-29 2007-12-28 ヒトｌｄｌ受容体に対するモノクローナル抗体
CN200780048492A CN101679524A (zh) 2006-12-29 2007-12-28 针对人类ldl受体的单克隆抗体
CA002661853A CA2661853A1 (fr) 2006-12-29 2007-12-28 Anticorps monoclonal dirige contre le recepteur humain des ldl
EP07872460A EP2167544A2 (fr) 2006-12-29 2007-12-28 Antocorps monoclonal dirige contre le recepteur humain des ldl
US12/519,275 US20100098706A1 (en) 2006-12-29 2007-12-28 Monoclonal antibody directed against the human ldl receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611546A FR2910896B1 (fr) 2006-12-29 2006-12-29 Anticorps monoclonal dirige contre le recepteur humain des ldl
FR0611546 2006-12-29

Publications (3)

Publication Number Publication Date
WO2008099071A2 WO2008099071A2 (fr) 2008-08-21
WO2008099071A3 WO2008099071A3 (fr) 2008-12-18
WO2008099071A8 true WO2008099071A8 (fr) 2009-10-22

Family

ID=38229736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/002187 WO2008099071A2 (fr) 2006-12-29 2007-12-28 Anticorps monoclonal dirigé contre le récepteur humain des ldl

Country Status (9)

Country Link
US (1) US20100098706A1 (fr)
EP (1) EP2167544A2 (fr)
JP (1) JP2010514434A (fr)
KR (1) KR20100014279A (fr)
CN (1) CN101679524A (fr)
AU (1) AU2007346741A1 (fr)
CA (1) CA2661853A1 (fr)
FR (1) FR2910896B1 (fr)
WO (1) WO2008099071A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139217A0 (en) * 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl

Also Published As

Publication number Publication date
FR2910896A1 (fr) 2008-07-04
CA2661853A1 (fr) 2008-08-21
JP2010514434A (ja) 2010-05-06
AU2007346741A1 (en) 2008-08-21
WO2008099071A2 (fr) 2008-08-21
CN101679524A (zh) 2010-03-24
EP2167544A2 (fr) 2010-03-31
KR20100014279A (ko) 2010-02-10
US20100098706A1 (en) 2010-04-22
WO2008099071A3 (fr) 2008-12-18
FR2910896B1 (fr) 2012-11-16

Similar Documents

Publication Publication Date Title
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
NZ598770A (en) Monoclonal antibodies
WO2008036688A3 (fr) Anticorps optimisés ciblant l'antigène hm1.24
NZ596295A (en) Anti-5T4 antibodies and uses thereof
NZ590860A (en) Fgf-r4 receptor-specific antagonists
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ587230A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
NZ594968A (en) Humanized c-kit antibody
NZ601271A (en) Cd127 binding proteins
RS52439B (en) HUMAN ANTIBODIES TO THE HUMAN DELTA SIMILAR LIGAND 4
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ZA200800555B (en) IL-1² binding antibodies and fragments thereof
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
WO2007117577A3 (fr) Anticorps humains à haute affinité dirigés contre le récepteur de l'il-18 humaine
WO2007137984A3 (fr) Immunoglobulines
SG10201804513WA (en) Antibodies Against Fcrn And Use Thereof
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
WO2006118772A3 (fr) Anticorops de fcrn et utilisations
WO2006113546A3 (fr) Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
WO2006113643A3 (fr) Anticorps monoclonaux entierement humains a affinite elevee d'interleukine-8 et epitopes destines a ces anticorps

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048492.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2661853

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007346741

Country of ref document: AU

Ref document number: 1020097013066

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009543504

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4311/DELNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007346741

Country of ref document: AU

Date of ref document: 20071228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007872460

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12519275

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872460

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0721197

Country of ref document: BR

Free format text: APRESENTE DOCUMENTOS COMPROBATORIOS QUE EXPLIQUEM A DIVERGENCIA NO NOME DO DEPOSITANTE CONSTANTE NA PUBLICACAO INTERNACIONAL WO2008/099071 DE 21/08/2008 "LFB BIOTECHNOLOGIES SOCIETE PAR ACTIONS SIMPLIFIEE UNIPERSONNELLE" E O CONSTANTE DA PETICAO INICIAL NO 016090003860 DE 17/06/2009 "LFB BIOTECHNOLOGIES".

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0721197

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2254 DE 18/03/2014.